research DataSheet2_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.
Search
for
Sort by
Research
150-180 / 1000+ results
research The Challenging Consultation: Management of Melanoma
The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.
research SnapshotDx Quiz: February 2018
Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.
research 원형탈모증(alopecia areata)의 최신 이해와 치료
New treatments for alopecia areata, like JAK inhibitors and immunomodulators, are promising.
research Proceedings of the Heinz Maurer-Symposium “Review and Preview in Science for Healthy Skin” June 28th 2014, Jakobsberg, Boppard, Germany
The symposium concluded that environmental factors significantly contribute to skin aging.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Case Report: A novel KRT74 variant in an eight-year-old boy with alopecia totalis successfully treated with baricitinib
Baricitinib successfully regrew hair in an 8-year-old boy with alopecia totalis linked to a KRT74 gene variant.
research Multiomics Analysis of the Response to Ritlecitinib in Alopecia Areata Subtypes and Correlation With Efficacy
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
research Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
research Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research 1326 Translation-dependent skin hyperplasia is promoted by type 1/17 inflammation in psoriasis
Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research The role of lymphocytes in the development and treatment of alopecia areata
Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.
research Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
Skin reactions from cancer treatments might predict how well the treatments work.
research Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
research Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
Nail changes from immunotherapy can be managed without stopping cancer treatment.
research Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Nivolumab can cause hair loss as a rare side effect.
research Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
research Cutaneous lupus erythematosus induced by tislelizumab
Tislelizumab can cause cutaneous lupus erythematosus.
research Immunotherapy-Induced Scarring Alopecia: A Case Series
Some patients on immune therapy for melanoma may develop scarring hair loss, but cancer treatment remains effective.
research Supplementary Material for: Immunotherapy-Induced Scarring Alopecia: A Case Series
Immune therapy for cancer can cause rare hair loss but doesn't stop treatment success.
research Supplementary Material for: Immunotherapy-Induced Scarring Alopecia: A Case Series
Immune therapy for cancer can cause hair loss scars in some patients.
research Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
Early intervention and tailored management are crucial for skin side effects in cancer treatments.
research Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
New and repurposed treatments are improving outcomes in dermatology.
research 44391 ICI Therapy Toxicities in Psoriasis
ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
Personalized treatments for hair loss focus on specific genetic and biological pathways.